The Oncology Institute, Inc. · NASDAQ:TOI

The Oncology Institute — Starling Oncology — Investor Presentation (November 2026)

29 slides from The Oncology Institute's investor presentation, Nov 12, 2026

  1. Slide 1: Forward-looking statements disclaimer

    Some of the information in this presentation is not historical in nature and may constitute forward - looking statements, which ar e made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward - looking

  2. Slide 2: Forward-looking statements disclaimer

    Some of the information in this presentation is not historical in nature and may constitute forward - looking statements, which ar e made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward - looking

  3. Slide 3: Investment Highlights

    3 Starling Oncology | Investor Presentation 5 4 3 2 1 A leading national oncology - focused VBC Platform Large TAM, with long - term growth driven by secular trends Balanced model with at - risk VBC and FFS ancillary services Multiple levers for growth across a diversified business Proven leadership

  4. Slide 4: High-Quality Care Delivery & Benefits Management Platform

    4 Starling Oncology | Investor Presentation High - Quality Care Delivery & Benefits Management Platform Benefits Management Platform Care Delivery Delegated provider network management Utilization and case management Drug formulary Claims adjudication Patient call center Community oncologists Nursin

  5. Slide 5: Starling Oncology At A Glance

    Starling Oncology At A Glance 5 Starling Oncology | Investor Presentation Note: 2026E reflects the midpoint of FY2026 revenue guidance of $650 – 660M, as provided in the Company’s 3Q’26 earnings release ( November 5, 2026). 1. Reflects all individually contracted plans and geographies OPERATIONAL FO

  6. Slide 6: Recent Announcements

    Recent Announcements 6 Starling Oncology | Investor Presentation Jul 7, 2026 Aug 3, 2026 4Q26 Aug 17, 2026 Repaid the $86M Deerfield note through a strategic refinancing with OrbiMed , strengthening the balance sheet while expanding revolver capacity to $25M Relaunched as Starling Oncology and began

  7. Slide 7: Oncology Care Costs Are Rising Rapidly

    (1) American Cancer Society. (2) National Cancer Institute. (3) Wall street research. (4) IQVIA Institute for Human Data Scie nce . Oncology Care Costs Are Rising Rapidly 7 Starling Oncology | Investor Presentation 2.1M+ New U.S. cancer diagnoses in 2026 (+25% vs. 2016) (1) $246B Total U.S. cancer c

  8. Slide 8: Fee-for-Service Oncology Misaligns Incentives

    (1) IQVIA. (2) AmerisourceBergen / Oncology Supply practice benchmarking. Fee - for - Service Oncology Misaligns Incentives 8 Starling Oncology | Investor Presentation U.S. ONCOLOGY SPEND 1 $99B → $180B U.S. oncology drug spending nearly doubles by 2028 (1) 2 ~$412K Median cost of a new oncology dru

  9. Slide 9: Starling Oncology Solutions and Scale

    Starling Oncology Solutions and Scale 9 Starling Oncology | Investor Presentation % OF REVENUE (1) Capitation Fixed per - member - per - month payments from payors to manage a population's oncology care. Fee - for - Service Billing insurance and copay for E&M visits, infusions, drug resale, and radi

  10. Slide 10: National Footprint with Significant Upside

    National Footprint with Significant Upside Non - CA markets are the growth engine — lives up 272% and revenue up 44% since 2024 Lives by State (Lives in thousands) Revenue by State ($ in millions) 1,813 1,765 67 249 1,880 2,015 2024 2025 $315 $391 $78 $112 $393 $503 2024 2025 CA Non - CA CA Non - CA

  11. Slide 11: Full-Spectrum Capitated Offering

    Starling Oncology’s Full - Spectrum Capitated Offering 11 Starling Oncology | Investor Presentation FUTURE OF STARLING ONCOLOGY GROWTH Narrow Network Capitation Starling Oncology contracts with providers that are globally capitated with a Knox - Keene license to serve as the exclusive oncology provi

  12. Slide 12: Narrow and Delegated Patient Pathways

    Step 1 Step 2 Step 3 Starling Oncology contracts with Payor to manage oncology care via: Oncology patients seen for capitated outpatient medical oncology services in Starling Oncology or network clinic STLN captures additional clinical revenue from services not included in capitation for outpatient

  13. Slide 13: Proven Ability to Maintain Stable MLR at Scale

    Proven Ability to Maintain Stable MLR at Scale Launched Delegated contract model and began on - boarding those patients 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 Consistent MLR Performance Despite Elevated Industry Utilization Cap Revenue ($M) (1) MLR (1)(2) MLR expected in 85 – 90% range over next 12

  14. Slide 14: Delegated Capitation: Health Plan Solution

    Delegated Contract Ramp Revenue Gross Margin 1 2 3 4 5 6 7 8 9 10 11 12 Months MONTHS 1 – 4 Transition of Care Period MONTHS 5 – 8 VBC Adoption MONTHS 9 – 12 Mature State Clinics Outside CA: Owned vs. Networked 23 24 25 67 222 2024 2025 2026 Delegated Members Growth & Diversification 4Q24 1Q25 2Q25

  15. Slide 15: Specialty Pharmacy Overview

    Revenue & Gross Margin $100M $180M $269M $29M $31M $46M 2023 2024 2025 Multi - Year Growth in Script Volume 8K 11K 20K 33K ~60K+ 2022 2023 2024 2025 2026E Scripts per 1K Visits & Clinic Visits 51K 51K 50K 52K 56K 51K 54K 56K 60K 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 102 115 122 156 184 208 22

  16. Slide 16: The Starling Oncology Care Model

    16 Starling Oncology | Investor Presentation The Starling Oncology Care Model Care Navigation Program with Proven Outcomes Accessible Community - based locations Comprehensive Hospital Coverage Integrated Medical and Radiation Oncology Well - recognized Physicians Internal Second - Opinion Network O

  17. Slide 17: Starling Oncology Nexus

    Starling Oncology Nexus (1) A proprietary industry - leading UM platform promoting provider engagement Starling Oncology | Investor Presentation (1) - Patent Pending 17 A unified platform for value - based care Starling’s proprietary platform connects utilization management, clinical pathways, real

  18. Slide 18: Starling Oncology Nexus Screenshots

    Starling Oncology Nexus Screenshots Starling Oncology | Investor Presentation 18

  19. Slide 19: Nexus Performance KPIs – Early Wins

    Nexus Performance KPIs – Early Wins Starling Oncology | Investor Presentation (1) Based on 3 months of 2026 data 19 >80% Minimum number of cases submitted weekly

  20. Slide 20: What Sets Starling Apart in a Competitive Landscape

    What Sets Starling Apart in a Competitive Landscape 20 Starling Oncology | Investor Presentation Care Delivery Model Provide Clinical Care Utilization Management Incentivized to Keep Drug Costs Low Purchasing Drugs at Scale Care Navigation Model Utilization Management Only Subsidiary of a Distributo

  21. Slide 21: Leadership Team

    = Daniel Virnich, MD Chief Executive Officer • Joined STLN in 2020 as COO, CEO since 2023 • 20+ years of executive leadership and value - based care operations experience • Previously, served as President of DaVita Medical Group, Florida and Senior VP of Operations for Healthcare Partners in Souther

  22. Slide 22: Financial Overview

    Financial Overview 22 Starling Oncology | Investor Presentation

  23. Slide 23: Financial Highlights

    23 Starling Oncology | Investor Presentation Financial Highlights 1 Diversified Revenue Base Revenue spans capitation, fee - for - service, specialty pharmacy, and clinical solutions, reducing reliance on any single payer model 2 Recurring, Visible Revenue Multi - year capitation contracts and recur

  24. Slide 24: Consistent Revenue Growth

    Consistent Revenue Growth 24 Starling Oncology | Investor Presentation Patient Lives (M) Adjusted EBITDA ($M) Revenue ($M) ($35.7) 2024 ($12.4) ($25.8) 2023 2025 $324M 2023 $393M 2024 $503M 2025 Capitated Revenue FFS Revenue Specialty Pharmacy Clinical Trials & Other $655M 2026E $3M - $5M 2026E Note

  25. Slide 25: 3Q26 Quarterly Results

    3Q26 Quarterly Results 25 Starling Oncology | Investor Presentation Notes: ​ (1) Adjusted EBITDA is a non - GAAP measure. A reconciliation to the nearest GAAP measure is available upon request. Revenue Adjusted EBITDA (1) Patient Lives 3Q26 Operational Highlights ($ in millions) ($ in millions) (mil

  26. Slide 26: Pharma Margin Bridge

    Pharma Margin Bridge Starling Oncology | Investor Presentation 26 Pharma Margin Drivers 18 – 19% +2 – 3% 21 – 24% Including Incremental Margin Opportunity 18 – 21% Baseline Margin Scaled Procurement Activities Opportunistic Pricing Current Margin Long - term Margin +0 – 2% Incremental Margin Opportu

  27. Slide 27: Path to Breakeven and Profitability

    Path to Breakeven and Profitability Levers 27 Starling Oncology | Investor Presentation SG&A historically declining as a Percentage of Revenue, Gross Margins Trending Higher Margin Levers Gross Margin • Leverage existing clinical labor • Drive Specialty Pharmacy, Clinical Research, and behavioral at

  28. Slide 28: Longer Term Guidance

    Longer Term Guidance 28 Starling Oncology | Investor Presentation FY2025 FY2026 2028 TARGETS REVENUE $502.7M GROSS PROFIT $76.4M ADJUSTED EBITDA $(12.4)M FREE CASH FLOW $(23.9)M REVENUE $650 – $6 6 0M + 30 % mid. GROSS PROFIT $10 7 – $110M +4 0 % mid. ADJUSTED EBITDA $ 4 – $ 6 M TURNS + FREE CASH FL

  29. Slide 29: Investment Highlights

    29 Starling Oncology | Investor Presentation 5 4 3 2 1 A leading national oncology - focused VBC Platform Large TAM, with long - term growth driven by secular trends Balanced model with at - risk VBC and FFS ancillary services Multiple levers for growth across a diversified business Proven leadershi

Starling Oncology — Investor Presentation (November 2026) on 6ix